Article

FDA to rule on fusion protein

Look for an FDA decision about Regeneron Pharmaceuticals? biologics license application (BLA) for a fusion protein (VEGF Trap-Eye) for the treatment of the neovascular form of age-related macular degeneration (AMD) by Aug. 20 now that the agency has granted the company?s request for priority review.

Tarrytown, NY-Look for an FDA decision about Regeneron Pharmaceuticals’ biologics license application (BLA) for a fusion protein (VEGF Trap-Eye) for the treatment of the neovascular form of age-related macular degeneration (AMD) by Aug. 20 now that the agency has granted the company’s request for priority review.

“We are very pleased that the FDA has chosen to grant priority review to [the fusion protein],” said Leonard S. Schleifer, MD, PhD, president and chief executive officer of Regeneron. “We look forward to working closely with the FDA to achieve our goal of bringing a new treatment option that offers a major advance to patients with AMD.”

Regeneron and Bayer HealthCare are collaborating on the development of the fusion protein for the treatment of wet AMD, central retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and other eye diseases and disorders.

Bayer HealthCare plans to submit a regulatory application outside of the United States in the first half of this year. If approved by authorities, Bayer HealthCare will market the fusion protein outside the United States, where the companies will share equally in profits from any future sales. Regeneron maintains exclusive rights to the fusion protein in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.